

The information in the press release is intended for investors.

Isofol appoints nomination committee ahead of the 2026 Annual General Meeting

GOTHENBURG, Sweden, November 4, 2025 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISO FOL), ("Isofol" or the "Company"), announced today that the members of the nomination committee for the Annual General Meeting 2026 have been appointed in accordance with the principles for appointing nomination committees that were adopted at the Annual General Meeting 2025.

According to the instructions for appointment of the nomination committee for Isofol, the nomination committee shall consist of three members appointed by the three largest shareholders in the company, based on the number of votes in the share register provided by Euroclear Sweden AB or other reliable information as of September 30, 2025. If any of the three largest shareholders waives their right to appoint a member to the nomination committee, the next largest shareholder shall be given the opportunity to appoint a member to the nomination committee until the nomination committee consists of at least three members. Another nomination committee member may be appointed by minority shareholders representing at least 10 percent of the votes based on the share register provided by Euroclear Sweden AB or other reliable information. The chairman of the nomination committee shall consist of the largest shareholder in terms of votes at the time of the nomination committee's appearance, unless the nomination committee agrees otherwise, and may not consist of the chairman of the board or another board member. The chairman of the board shall not be part of the nomination committee but is normally a co-opted member at its meetings.

The nomination committee ahead of the AGM 2026 consists of the following members:

- **Christian Haglund**, representing approximately 4.72 percent of the shares and votes
- **Johan Möller**, *chairman of the nomination committee*, appointed by Hans Enocson representing approximately 2.70 percent of the shares and votes,
- **Göran Gustafsson**, representing approximately 2.17 percent of the shares and votes and
- **Lars Lind**, appointed by a minority of owners representing approximately 14.13 percent of shares and votes.

The members of the nomination committee are appointed by owners who represent a total of approximately 23.72 percent of the total number of shares and votes in Isofol according to the ownership conditions as of September 30, 2025.

Information about the nomination committee's work and the instructions to the nomination committee can be found on the company website under the section for Corporate Governance. The nomination committee's proposal will be presented in the summons to the annual general meeting 2026 and on the company's website, www.isofofmedical.com.

Shareholders who wish to submit proposals to the nomination committee shall do this in writing by sending an e-mail to valberedningen@isofolmedical.com (heading: "Isofol's nomination committee") or by mail to the following address:

Isofol Medical AB (publ)

Att. Valberedningen
Arvid Wallgrens Backe 20
413 46 GOTHENBURG
SWEDEN

Any proposals must be received by the nomination committee no later than February 28, 2026, to be included in the notice and agenda for the Annual General Meeting 2026.

The Annual General Meeting in Isofol Medical AB (publ) will be held on May 19, 2026, in Gothenburg.

For more information, please contact

Jan-Eric Österlund, Chairman of the board
E-mail: jan-eric.osterlund@isofolmedical.com
Phone: +44 7785 368 155

Isofol Medical AB (publ)

Petter Segelman Lindqvist, Chief Executive Officer
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0)739 60 12 56

The information was submitted for publication, through the agency of the contact person set out above, at 09:45 CET on November 4, 2025.

About Isofol

Isofol works to improve the quality of life and prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is truly urgent. A phase Ib/II study is now being conducted with a new dosage regimen that is expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.

www.isofolmedical.com